Related Experiment Video
Updated: May 13, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab
David S Kirwin1, Travis Frantz1, Colin F Nolan2
1Naval Medical Center San Diego, San Diego, California, USA.
Insights
Pediatric generalized pustular psoriasis (GPP) is a rare condition. A new study identifies Mediterranean fever gene (MEFV) variants as a risk factor, highlighting the need for genetic research in childhood autoinflammatory diseases.
Area of Science:
- Pediatric Dermatology
- Genetics
- Immunology
Background:
- Pediatric generalized pustular psoriasis (GPP) is a rare, severe childhood skin condition.
- Early-onset GPP is often linked to interleukin-36 receptor antagonist (DITRA) deficiency.
Observation:
- A case study involved a pediatric patient diagnosed with GPP.
- The patient was found to have a heterozygous variant in the Mediterranean fever gene (MEFV).
Findings:
- MEFV variants represent a newly identified genetic risk factor for GPP.
- The patient's GPP was successfully treated with adalimumab.
Implications:
- This case underscores the importance of genomic studies in pediatric autoinflammatory diseases.
- Evidence-based management strategies are crucial for challenging pediatric GPP cases.
Abstract:
Pediatric generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening variant of childhood psoriasis. Early-onset GPP has a well-known association with deficiency of the interleukin-36 receptor antagonist (DITRA). We present a case of a pediatric patient diagnosed with GPP found to have a heterozygous variant in the Mediterranean fever gene (MEFV) that was successfully treated with adalimumab. MEFV variants are a newly identified genetic risk factor for GPP. Our case highlights the need for ongoing genomic studies for childhood autoinflammatory diseases and the call for evidence-based management for these challenging cases.

